The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.
 
Jingquan Jia
No Relationships to Disclose
 
Donna Niedzwiecki
No Relationships to Disclose
 
Christy Arrowood
No Relationships to Disclose
 
Nancy Garett-Mead
No Relationships to Disclose
 
Rebecca Nagy
Employment - Guardant Health; Guardant Health; Guardant Health; Guardant Health
Stock and Other Ownership Interests - Guardant Health; Guardant Health; Guardant Health; Guardant Health
 
Richard B. Lanman
Employment - Guardant Health; Guardant Health; Guardant Health; Guardant Health; Veracyte; Veracyte; Veracyte; Veracyte
Leadership - Biolase; Biolase; Biolase; Biolase; Guardant Health; Guardant Health; Guardant Health; Guardant Health
Stock and Other Ownership Interests - Biolase; Biolase; Biolase; Biolase; Forward; Forward; Forward; Forward; Guardant Health; Guardant Health; Guardant Health; Guardant Health
Consulting or Advisory Role - Forward; Forward; Forward; Forward
Research Funding - Guardant Health; Guardant Health; Guardant Health; Guardant Health
 
John Wright
No Relationships to Disclose
 
Andrew B. Nixon
Consulting or Advisory Role - GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Kanghong Pharma; Kanghong Pharma; Kanghong Pharma; Kanghong Pharma; Lilly; Lilly; Lilly; Lilly
Research Funding - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Eureka Therapeutics; Eureka Therapeutics; Eureka Therapeutics; Eureka Therapeutics; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; HTG Molecular Diagnostics; HTG Molecular Diagnostics; HTG Molecular Diagnostics; HTG Molecular Diagnostics; Leadiant Biosciences; Leadiant Biosciences; Leadiant Biosciences; Leadiant Biosciences; medpacto; medpacto; medpacto; medpacto; Novartis; Novartis; Novartis; Novartis; Seagen; Seagen; Seagen; Seagen; TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent (Inst); Patent (Inst); Patent (Inst); Patent (Inst); Patent Pending (Inst); Patent Pending (Inst); Patent Pending (Inst); Patent Pending (Inst)
Travel, Accommodations, Expenses - TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma
 
John H. Strickler
Stock and Other Ownership Interests - OncoMed; OncoMed; OncoMed; OncoMed
Honoraria - Chugai/Roche; Chugai/Roche; Chugai/Roche; Chugai/Roche
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; OncoMed; OncoMed; OncoMed; OncoMed; Proteus Digital Health; Proteus Digital Health; Proteus Digital Health; Proteus Digital Health; Seagen; Seagen; Seagen; Seagen
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Cascadian Therapeutics (Inst); Cascadian Therapeutics (Inst); Cascadian Therapeutics (Inst); Cascadian Therapeutics (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); Macrogenics (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)